Clinical Trial Detail

NCT ID NCT01828112
Title LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Docetaxel

Pemetrexed Disodium

Ceritinib

Age Groups: adult

Additional content available in CKB BOOST